Old sedative, new trick: amobarbital may shield the heart during bypass surgery
NCT ID NCT06757868
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial investigates whether a single dose of amobarbital, an older sedative, can protect the heart muscle in adults undergoing cardiac surgery with a heart-lung machine. Researchers will measure how quickly the heart restarts after bypass and track recovery times and heart damage markers. The goal is to see if this inexpensive drug can improve surgical outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
amobarbital
What this could lead to
If it works, this could point toward a simple, low-cost way to protect the heart during surgery and speed up recovery.
What could go wrong
This is a small, early-stage trial with 80 people, so results may not apply to everyone. Amobarbital is a sedative and may cause side effects like drowsiness or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOPULMONARY BYPASS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji hospital
Wuhan, Hubei, 430030, China